X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VIR-3434 (tobevibart) is an investigational subcutaneously administered antibody designed to block entry of hepatitis B and hepatitis delta viruses into hepatocytes. It is being evaluated in combination with elebsiran for the treatment of chronic hepatitis D.
Lead Product(s): Tobevibart,Elebsiran
Therapeutic Area: Infections and Infectious Diseases Product Name: VIR-3434
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
Under the termination, partners have ended their collaboration on anti-influenza antibodies, including VIR-2482, an investigational hemagglutinin targeting, intramuscularly administered influenza A-neutralizing monoclonal antibody.
Lead Product(s): VIR-2482
Therapeutic Area: Infections and Infectious Diseases Product Name: VIR-2482
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $345.0 million Upfront Cash: $225.0 million
Deal Type: Termination January 23, 2024
Details:
The funding will be used to advance the development of novel monoclonal antibody (mAb) candidates, including VIR-7229, and delivery solutions to widen the applicability of mAbs in COVID-19 and in pandemic preparedness and response.
Lead Product(s): VIR-7229
Therapeutic Area: Infections and Infectious Diseases Product Name: VIR-7229
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 03, 2023
Details:
VIR-1388 is an investigational subcutaneously administered HIV T cell vaccine based on HCMV that has been designed to elicit abundant T cells that recognize HIV proteins in a way that differs from prior investigational HIV vaccines.
Lead Product(s): VIR-1388
Therapeutic Area: Infections and Infectious Diseases Product Name: VIR-1388
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
VIR-2482 is an investigational hemagglutinin targeting, intramuscularly administered influenza A-neutralizing monoclonal antibody. In vitro, it has been shown to cover all major strains of influenza A that have arisen since the 1918 flu pandemic.
Lead Product(s): VIR-2482
Therapeutic Area: Infections and Infectious Diseases Product Name: VIR-2482
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
Combinations of VIR-3434, VIR-2218, pegylated interferon alpha (PEG-IFNα) and a nucleoside reverse transcriptase inhibitor (NRTI) are being investigated in hepatitis B virus (HBV) immune-active, treatment-naïve adults.
Lead Product(s): VIR-2218,VIR-3434
Therapeutic Area: Infections and Infectious Diseases Product Name: VIR-2218
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
The new grant will support its novel T cell vaccine platform phase 1 clinical development of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV). VIR-1388 is based on the human cytomegalovirus (HCMV) vector platform.
Lead Product(s): VIR-1388
Therapeutic Area: Infections and Infectious Diseases Product Name: VIR-1388
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 02, 2023
Details:
Xevudy (sotrovimab) is a mAb that treats mild-to-moderate COVID-19 by binding to and neutralizing the spike protein of SARS-CoV-2. It is also been designed to achieve high concentration in lungs to ensure optimal penetration into airway tissues affected by virus.
Lead Product(s): Sotrovimab
Therapeutic Area: Infections and Infectious Diseases Product Name: Xevudy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
Vir retains the sole rights for advancing next-generation solutions for COVID-19 and other coronavirus outbreaks. The Companies will continue to collaborate on Xevudy (sotrovimab) and VIR-7832 and to develop new therapies for influenza and other respiratory diseases.
Lead Product(s): Sotrovimab
Therapeutic Area: Infections and Infectious Diseases Product Name: Xevudy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 13, 2023
Details:
VIR-2482 is an investigational intramuscularly administered influenza A-neutralizing monoclonal antibody. In vitro, it has been shown to cover all major strains of influenza A that have arisen since the 1918 Spanish flu pandemic.
Lead Product(s): VIR-2482
Therapeutic Area: Infections and Infectious Diseases Product Name: VIR-2482
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
